You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Novel Coronavirus Infection

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Infection Trial in Nanjing, Nantong, Xuzhou (no intervention)

Recruiting
  • COVID-19 Infection
  • no intervention
  • Nanjing, Jiangsu, China
  • +2 more
Jan 28, 2023

Covid-19 Infection in Patients With Underlying Diseases

Not yet recruiting
  • Chronic Liver Disease
  • +3 more
  • underling disease
  • (no location specified)
Aug 1, 2023

COVID-19 Trial in Atlanta (Duvelisib, Placebo)

Completed
  • COVID-19
  • Atlanta, Georgia
  • +2 more
Jun 10, 2022

Acute Pancreatitis Complicated With COVID-19

Not yet recruiting
  • Acute Pancreatitis
  • 2019 Novel Coronavirus Infection
    • (no location specified)
    Feb 13, 2023

    COVID-19 Trial (Manzi Guben granules)

    Not yet recruiting
    • COVID-19
    • Manzi Guben granules
    • (no location specified)
    Feb 8, 2023

    Coronavirus Infection Trial in Moscow (Probiotics)

    Completed
    • Coronavirus Infection
    • Probiotics
    • Moscow, Russian Federation
      I.M. Sechenov First Moscow State Medical University
    Jan 13, 2022

    COVID-19, Child, Only Trial in Qingdao (Jinzhen oral liquid or Jinhuaqinggan granules)

    Recruiting
    • COVID-19
    • Child, Only
    • Jinzhen oral liquid or Jinhuaqinggan granules
    • Qingdao, Shandong, China
      Phase I Clinical Research Center
    Aug 17, 2022

    COVID-19, Hypoxia Trial in Richmond (L-ascorbic acid)

    Completed
    Has Results
    • COVID-19
    • Hypoxia
    • L-ascorbic acid
    • Richmond, Virginia
      Hunter Holmes Mcguire Veteran Affairs Medical Center
    Feb 23, 2022

    COVID-19 Trial in Shijiazhuang (Umbilical cord mesenchymal stem cells implantation, Comparator)

    Recruiting
    • COVID-19
    • Umbilical cord mesenchymal stem cells implantation
    • Comparator
    • Shijiazhuang, Hebei, China
      The First Hospital of Hebei Medical University
    Feb 22, 2023

    COVID-19 Trial in Chengdu (VV116+SOC, SOC)

    Recruiting
    • COVID-19
    • Chengdu, Sichuan, China
      Chengdu Zenitar Biomedical Technology Co., Ltd
    Feb 3, 2023

    2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease Trial (Famotidine, Celecoxib, Placebo)

    Not yet recruiting
    • 2019 Novel Coronavirus Disease
    • +11 more
    • (no location specified)
    Aug 15, 2022

    Prognostic Value of PtcO2 in Patients With COVID-19

    Recruiting
    • COVID-19 Acute Respiratory Distress Syndrome
    • outcome
    • Subtype of COVID-19
    • Nanjing, Jiangsu, China
      Zhongda hospital
    Jan 10, 2023

    2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease Trial in Miami (Famotidine, Celecoxib,

    Active, not recruiting
    • 2019 Novel Coronavirus Disease
    • +11 more
    • Miami, Florida
      US02-04: Integrated Health Solutions
    Aug 15, 2022

    2019 Novel Coronavirus Infection Trial in Shanghai (PVP-I Nasal Irrigation and gargling)

    Recruiting
    • 2019 Novel Coronavirus Infection
    • PVP-I Nasal Irrigation and gargling
    • Shanghai, Shanghai, China
      Ruijin Hospital,Shanghai Jiaotong University school of medicine
    May 17, 2022

    AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in Diagnosis

    Completed
    • 2019 Novel Coronavirus Disease
    • +8 more
    • Diagnostic Test: Diagnostic Software as Medical Device
    • Sunrise, Florida
      Sunrise Research Institute
    Jul 19, 2022

    Pharmacokinetics, Safety Issues, Efficacy Trial in Russian Federation (GP30341 capsules 200 mg, Standard therapy)

    Completed
    • Pharmacokinetics
    • +2 more
    • GP30341 capsules 200 mg
    • Standard therapy
    • Kaliningrad, Russian Federation
    • +4 more
    Dec 7, 2022

    Covid19 Trial in Shijiazhuang (Novel coronavirus infection)

    Completed
    • Covid19
    • Novel coronavirus infection
    • Shijiazhuang, Hebei, China
      Shijiazhuang Fifth Hospital
    Jun 11, 2021

    Long-term Impact of Infection With Novel Coronavirus (COVID-19)

    Recruiting
    • COVID
      • San Francisco, California
        Zuckerberg San Francisco General Hospital (ZSFG)
      Mar 22, 2022

      Asthenia, COVID-19 Trial in Russian Federation (Ethyl methyl hydroxypyridine succinate + Meldonium, Placebo)

      Completed
      • Asthenia
      • COVID-19
      • Ethyl methyl hydroxypyridine succinate + Meldonium
      • Placebo
      • Moscow, Russian Federation
      • +5 more
      Jan 18, 2023

      SARS-CoV-2 Infection Trial in Washington (Coronavirus-specific T cell (CST))

      Recruiting
      • SARS-CoV-2 Infection
      • Coronavirus-specific T cell (CST)
      • Washington, District of Columbia
      • +1 more
      Sep 1, 2022

      PHenotyping patiENts Admitted to Hospital With cOvid-19

      Recruiting
      • Coronavirus
      • +4 more
        • London, United Kingdom
          Chelsea and Westminster Hospital
        Aug 5, 2021

        Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases

        Active, not recruiting
        • Covid19
        • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Feb 15, 2022

        2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease Trial in United States (Famotidine,

        Terminated
        • 2019 Novel Coronavirus Disease
        • +11 more
        • Newport Beach, California
        • +14 more
        Jul 20, 2022

        2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection Trial in Tucson (USB002, Placebo)

        Recruiting
        • 2019 Novel Coronavirus Infection
        • +5 more
        • Tucson, Arizona
          The University of Arizona Health Sciences Center/ Banner Healthc
        Aug 2, 2021

        Covid19, ME/CFS, SARS COV2 Trial in United States

        Active, not recruiting
        • Covid19
        • +5 more
          • Los Angeles, California
          • +7 more
          Sep 1, 2022